Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $3.9900 (-2.21%) ($3.9900 - $3.9900) on Tue. Dec. 14, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.28% (three month average) | RSI | 41 | Latest Price | $3.9900(-2.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.7% a day on average for past five trading days. | Weekly Trend | HTBX declines -3.8% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(52%) ARKG(51%) ARKK(51%) ONLN(50%) EEM(49%) | Factors Impacting HTBX price | HTBX will decline at least -1.14% in a week (0% probabilities). VXX(-40%) VIXM(-39%) UUP(-14%) TLT(-13%) GLD(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.14% (StdDev 2.28%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $4.29 | 5 Day Moving Average | $4.11(-2.92%) | 10 Day Moving Average | $4.09(-2.44%) | 20 Day Moving Average | $4.29(-6.99%) | To recent high | -37% | To recent low | 1.5% | Market Cap | $439m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |